STOCK TITAN
  1. Home
  2. News
  3. LIVN

LivaNova PLC - LIVN STOCK NEWS

Welcome to our dedicated news page for LivaNova PLC (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LivaNova PLC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LivaNova PLC's position in the market.

News
LivaNova Reports Third-Quarter 2023 Results
Rhea-AI Summary
LivaNova PLC reported Q3 2023 results with revenue of $286.1 million, a 13.3% increase on a reported basis and a 12.1% increase on a constant-currency basis compared to the prior-year period. The company raised its full-year 2023 revenue and adjusted diluted earnings per share guidance. Cardiopulmonary revenue increased 19.7% and Neuromodulation revenue increased 5.8%. Third-quarter 2023 operating income was $4.5 million, compared to an operating loss of $132.0 million in Q3 2022. Adjusted operating income for Q3 2023 was $45.0 million. LivaNova now expects full-year 2023 revenue to grow between 9% and 11% on a constant-currency basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
earnings
-
News
LivaNova to Present at the Stifel and Wolfe Healthcare Conferences
Rhea-AI Summary
LivaNova PLC's Interim CEO and Board Chair, Bill Kozy, will present a general business update at two healthcare conferences in New York in November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
News
LivaNova Board Appoints J. Christopher Barry as New Director
Rhea-AI Summary
LivaNova appoints J. Christopher Barry to its Board of Directors and announces the retirement of Andrea Saia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
management
News
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
Rhea-AI Summary
LivaNova announces retirement of President of Cardiopulmonary Business Unit, Marco Dolci, by December 31, 2023. Franco Poletti appointed as Interim General Manager. A search for a permanent successor will be conducted. Dolci's leadership during the pandemic and launch of Essenz Perfusion System acknowledged. Smooth transition expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
-
News
LivaNova to Announce Third-Quarter 2023 Results
Rhea-AI Summary
LivaNova to discuss Q3 2023 results in conference call on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
earnings
-
News
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
Rhea-AI Summary
LivaNova receives FDA clearance for Essenz In-Line Blood Monitor, enhancing patient care during cardiopulmonary bypass procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
clinical trial
News
LivaNova to Present at the Baird Global Healthcare Conference
Rhea-AI Summary
LivaNova CEO to present at Baird Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
-
News
LivaNova Reports Second-Quarter 2023 Results
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) reported Q2 2023 results with a 15.6% increase in revenue to $293.9 million and raised full-year 2023 guidance. Cardiopulmonary revenue increased by 20.9% and Neuromodulation revenue increased by 13.5% compared to the prior year. Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.55 to $2.75.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.87%
Tags
earnings
-
News
LivaNova to Announce Second-Quarter 2023 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
earnings
News
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
clinical trial
Stock LIVN logo
LivaNova PLC

Nasdaq:LIVN

LIVN Rankings

#1579 Ranked by Market Cap
#1984 Ranked by Stock Gains
N/A Ranked by Dividends

LIVN Stock Data

2.86B
53.65M
0.5%
104.81%
6.14%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United Kingdom
20 Eastbourne Terrace

About LIVN

livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.